Other publications (selection, from 2012 and older)

  • Lubbe SJ, et al. Comprehensive evaluation of the impact of 14 genetic variants on colorectal cancer phenotype and risk. Am J Epidemiol 2012;175(1):1-10.
  • Lubbe SJ, et al. The 14q22.2 colorectal cancer variant rs4444235 shows cis-acting regulation of BMP4. Oncogene 2011 Dec 12.[Epub ahead of print]
  • Jones AM, et al. TERC polymorphisms are associated both with susceptibility to colorectal cancer and with longer telomeres. Gut 2012;61(2):248-54.
  • Castellv√≠-Bel S, et al. Seeking genetic susceptibility variants for colorectal cancer: the EPICOLON consortium experience. Mutagenesis 2012;27(2):153-9.
  • Houlston RS; members of COGENT. COGENT (COlorectal cancer GENeTics) revisited. Mutagenesis 2012;27(2):143-51.
  • Fernandez-Rozadilla C, et al. Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. Pharmacogenomics J 2012 Feb 7.[Epub ahead of print]
  • Dunlop MG, et al. Cumulative impact of common genetic variants and other risk factors on colorectal cancer risk in 42 103 individuals. Gut 2012 May 22. [Epub ahead of print]
  • Dunlop MG, et al. Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet 2012;44(7):770-776.
COST is supported by the EU Framework Programme Horizon 2020